Drug-specific safety signal prioritization of antibody-drug conjugates in breast cancer: integrating FAERS pharmacovigilance, machine learning, and clinical contextualization
Yuhan Tang, Shaochun Liu, Yingze Zhu, Linlin Fan, Xiaoxi Han, Wenjie Ma, Haolu Zhang, Zhiqi Sui, Hui Pang, Wenhui Zhao · 2026
Read Drug-specific safety signal prioritization of antibody-drug conjugates in breast cancer: integrating FAERS pharmacovigilance, machine learning, and clinical contextualization by Yuhan Tang, Shaochun Liu, Yingze Zhu, Linlin Fan, Xiaoxi Han, Wenjie Ma, Haolu Zhang, Zhiqi Sui, Hui Pang, Wenhui Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597761.txt.
Description
Yuhan Tang and co-authors rank safety signals for a class of targeted cancer drugs used in breast cancer, in a study from 2026. These drugs link an antibody to a cell-killing payload. Three of them are in wide use, and their harm patterns differ. Raw side-effect reports are hard to read, since anyone can file them.
The team mined more than thirteen thousand reports tied to breast cancer. They checked eleven harms of special interest and used machine learning to rank which reports deserved a close look. One drug stood out for lung harm, another for blood and gut harm, and the third for liver harm. A small hospital group matched those patterns. The authors stress the counts are signals, not true risk rates. The ranking helps watch teams spend their time where it counts.
Catalog record
| CREATOR | Yuhan Tang, Shaochun Liu, Yingze Zhu, Linlin Fan, Xiaoxi Han, Wenjie Ma, Haolu Zhang, Zhiqi Sui, Hui Pang, Wenhui Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |